|
Synonyms: ATRN-119 | ATRN119 | compound P(4) [US20170226130]
Compound class:
Synthetic organic
Comment: Mosipasertib is the INN for a serine/threonine kinase inhibitor with antineoplastic potential that was included in WHO INN Proposed List 135 (July 2026). Structure matches exist in patents that claim macrocyclic ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors that are held by Atrin Pharmaceuticals [2], whose lead asset was the orally bioavailable ATR inhibitor ATRN-119. Atrin Pharmaceuticals was subsequently acquired by Aprea Therapeutics. The code name-to-INN association is confirmed on Aprea's pipeline webpage [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| ATRN-119 was progressed as a clinical stage anti-tumour agent, in both solid tumours and haematological cancers. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04905914 | Study Of ATRN-119 In Patients With Advanced Solid Tumors | Phase 1/Phase 2 Interventional | Aprea Therapeutics | ||
| NCT07578467 | Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs | Phase 1/Phase 2 Interventional | Abramson Cancer Center at Penn Medicine | ||
| NCT07617363 | ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS | Phase 1 Interventional | Washington University School of Medicine | ||